Active Ingredient(s): Obiltoxaximab
FDA Approved: * March 18, 2016
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Anthim Overview

Obiltoxaximab (ETI-204, trade name Anthim) is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1] This drug was developed by Elusys Therapeutics, Inc. References ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association. vteMonoclonal antibodies for infectious disease and toxinsFungal ("-fung-")Human ("-fungu-") Efungumab† Viral ("-v(i)[r]-")H...

Read more Anthim Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Anthim Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 600mg/6ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Anthim: (1 result)

Sorted by National Drug Code
  • 69604-204 Anthim 100 mg/ml Intravenous Solution by Elusys Therapeutics, Inc.

Other drugs which contain Obiltoxaximab or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA